News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

4-Antibody AG to Relocate to New Labs in Basel



5/6/2011 9:57:38 AM

Basel, Switzerland, 6th May, 2011: 4-Antibody AG, a leading Swiss antibody discovery company today announced that the Company will be relocating its Basel head offices and labs in June 2011 to the newly opened Technology Park Basel, which is part of the Stücki Business Park in Basel-Kleinhüningen.

The company’s new location is part of a new facility being opened today by Councillor Christoph Brutschin, Head of the Department for Economic, Social and Environmental Affairs for the Canton Basel-Stadt. The Technology Park Basel is supported by the Canton Basel-Stadt and the federal agency SECO and provides infrastructure for growing ‘high tech’ companies, particularly from the life sciences sector which are looking for fully equipped laboratory facilities. The Technology Park is located next to the ‘Basel Incubator’, managed by the start-up agency EVA and supported by the University of Basel, the Fachochschule Nordwestschweiz, and the Canton Basel-Stadt. The combination of the ‘Basel Incubator’ for emerging companies and growing companies relocating to the Technology Park is expected to create a new, dynamic, ‘high tech‘ life sciences ‘hub’ within Basel. 4-Antibody is the Technology Park’s first tenant.

Dr Ulf Grawunder, 4-Antibody’s CSO, said:

“Being able to upgrade our Basel lab facilities with this move to the Technology Park is another strong indication of the momentum being created by 4-Antibody’s exciting antibody discovery platform. We feel privileged to be the first tenants in this new world-class facility and expect that many other biotech companies in the region will follow in our footsteps. These new Basel lab facilities and our existing labs in Jena are both state of the art”

About 4-Antibody AG

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells (the cell designed by nature for optimal antibody display). This in vitro process is supported by the in vivo HU-PAC® filter, used to select only those antibody product candidates with the most desirable drug characteristics. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. The Company’s lead development product is an anti-cytomegalovirus antibody drug. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany. For more information please visit: www.4-antibody.com

Further Information:

Dr Robert Burns

CEO

4-Antibody AG

t: +41 61 697 1351

e: robert.burns@4-antibody.com

Dr Douglas Pretsell

Associate Partner

College Hill

t: +44 20 7866 7868

e: douglas.pretsell@collegehill.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES